

# Analgesic drug to prevent post surgery neuropathic pain



HEALTH  
NEUROLOGY

## ERADICATE NEUROPATHIC PAIN WITH EXPECTED REDUCED SIDE-EFFECT

Neuropathic pain induced by surgical interventions is a major public health problem because available treatments display side-effects and weak efficiency.

Our research team has developed a new asset that consist in :

1 | Repurposing of **Memantine**, an antagonist of NMDA (N-Methyl-D-Aspartate) receptors usually prescribed for Alzheimer's disease to prevent neuropathic pain following surgical interventions like mastectomy.

2 | Reduction of analgesics consumption and improvement of emotional state




## Competitive Advantages

- Response to unmet therapeutic need
- Attractive to speed up drug development
- Contribute to life quality improvement
- Preventive analgesic effects
- Non-opioid

## Development Status

- **Clinical POC validated** in a randomized clinical trial on 40 women undergoing mastectomy.



Compared with placebo, patients receiving Memantine showed a significant reduction in post-mastectomy pain intensity, reduced use of analgesic at 3 months and an improved emotional state.

## Business Opportunities

- Chronic pain treatment

### #Keywords

Neuropathic pain  
Drug repurposing  
NMDA receptor antagonist  
Memantine

### Research Team

UMR 1107 Inserm/UCA  
NEURO-DOL  
Clermont-Ferrand, France  
Pr. Gisèle PICKERING

### Partnership

Licensing or co-development

### Intellectual Property

FR2980973 / WO2013053746  
Priority filing in 2011  
Requests filed in EP / US

**SATT** | SOCIÉTÉ  
GRAND CENTRE | D'ACCÉLÉRATION  
DU TRANSFERT  
DE TECHNOLOGIE

### Contact

Magali **GRANGER**  
Business Developer  
T. +33 (0)6 34 22 36 89  
magali.granger@sattgc.com

### SATT Grand Centre

CLERMONT-FERRAND | LA ROCHELLE | LIMOGES |  
ORLÉANS | POITIERS | TOURS

Head Office : 8, rue Pablo Picasso  
63000 CLERMONT-FERRAND - FRANCE

[www.sattgc.com](http://www.sattgc.com)